One step closer to personalized medicine

On September 21-23, 2015, the p-medicine consortium composed of 19 partner organisations from all over Europe and Japan came together for their final project meeting in Homburg/Saar, Germany. During the meeting, the project's final achievements were presented to representatives of the European Commission, the local government as well as interested companies, research institutions and patient/parents groups.

The project’s research resulted in a series of computer-based tools, which will help cancer patients to better understand the nature of their disease and support clinicians in finding the right treatment for the individual patient by analyzing ‘big data’ from individual patients. In the end, these tools will help not only to facilitate the communication between doctors and patients and guide them to make decisions about the patient’s treatment together but will help researchers to detect new knowledge out of shared and joined health data combined with open access data.

Prof. Norbert Graf, coordinator of p-medicine, states in an interview: "The p-medicine project is facing the situation that even large diseases like breast cancer are divided into different subtypes. And each of these subtypes needs different treatment. To get these treatments to the correct patient, we need tools that are developed in p-medicine."

In the meeting's "public session", where the results of the project were presented to around 55 participants, emphasis was on the topics of patient empowerment and the progress made with regard to addressing legal and ethical requirements related to an infrastructure in which large sets of data are shared among numerous parties. Big data issues in general were also addressed by two key note speakers from Japan and the US. The public session closed with an outlook on STaRC, the Study Trial and Research Center to be found by a core team of p-medicine under the lead of Prof. Norbert Graf.

The second part of the meeting was a closed session dedicated to the evaluation of the project by the EC. The meeting ended with a very positive assessment by the EC officer and the reviewers regarding the technical implementation of the project. They particularly stressed the excellent leadership of this 19-partner project by p-medicine’s coordinator Prof. Norbert Graf.

The EU FP7 project p-medicine was one of a number of research projects arising from the broader VPH (Virtual Physiological Human) community. Research in p-medicine was devoted to creating an infrastructure that would facilitate the translation from current practice to personalised and preventive medicine. The emphasis was on formulating an open, modular framework of tools and services, so that p-medicine can be adopted gradually, including efficient secure sharing and handling of large personalized data sets and building standards-compliant tools and models. Privacy, non-discrimination, and access policies were aligned to maximize protection of and benefit to patients.

For further information, please visit:
http://www.p-medicine.eu

About p-medicine project
'p-medicine - From data sharing and integration via VPH models to personalized medicine' is a 4-year Integrated Project co-funded under the European Community's 7th Framework Programme aiming at developing new tools, IT infrastructure and VPH models to accelerate personalized medicine for the benefit of the patient.

In p-medicine 19 partners from 9 European countries and Japan have dedicated themselves to create support and sustain new knowledge and innovative technologies to overcome current problems in clinical research and pave the way for a more individualized therapy.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...